Medpace Holdings, Inc.

NasdaqGS MEDP

Medpace Holdings, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 17.65%

Medpace Holdings, Inc. Net Income Margin is 17.65% for the Trailing 12 Months (TTM) ending September 30, 2024, a 15.20% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Medpace Holdings, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 15.32%, a -7.05% change year over year.
Medpace Holdings, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 16.49%, a -0.98% change year over year.
Medpace Holdings, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 16.65%, a 20.34% change year over year.
Medpace Holdings, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 13.83%, a 22.32% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGS: MEDP

Medpace Holdings, Inc.

CEO	Dr. August James Troendle M.D.
IPO Date	Aug. 11, 2016
Location	United States
Headquarters	5375 Medpace Way
Employees	5,900
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Key trends

Past 5 years